Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

Publisher Website
Google Scholar
Abstract
The testing of the recently developed replication-defective recombinant chimpanzee adenovirus type 3–vectored ebolavirus vaccine (cAd3-EBO) is based on a demonstration of efficacy in a nonhuman primate model1 and on findings of low levels of preexisting anti-cAd3 antibody in serum samples obtained from European participants.2 The preliminary results of a phase 1 trial of the vaccine have been reported by Ledgerwood et al.,3 and the phase 2–3 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) trial (ClinicalTrials.gov number, NCT02344407) is currently under way. However, questions remain about the preexisting immunity to chimpanzee adenoviruses among African residents.